<DOC> 
<DOCNO>1080423_business_story_9175370.utf8</DOCNO> 
<TEXT> 
         
The Telegraph - Calcutta (Kolkata) | Business | Drug duo formalise alliance
                                                                                                                                                                                                                                                                                                                                                             Drug duo formalise alliance
          OUR CORRESPONDENT                                              Malvinder Mohan Singh in New Delhi on Tuesday. A Telegraph picture      
	New Delhi, April 22: Ranbaxy Laboratories has entered into a strategic alliance with Orchid Chemicals amp; Pharmaceuticals, after picking up a 14.7 per cent stake in the company.        
	Malvinder Mohan Singh, CEO and MD of Ranbaxy, said, Orchid is a niche player in the global pharmaceutical industry with an impressive track record, particularly in sterile products. We are pleased to enter into this long-term strategic alliance with Orchid. The agreement will be mutually beneficial, allowing both organisations to leverage their inherent strengths.        
	Ranbaxy Laboratories has entered into a business alliance agreement involving multiple geographies and therapies for both finished dosage formulations and active pharmaceutical ingredients.        
	K. Raghavendra Rao, managing director of Orchid Chemicals, said, Ranbaxys global scale and market reach and Orchids state-of-the-art development and manufacturing capabilities will expand the business of both the companies. We believe this will be a win-win arrangement for both.        
	Ranbaxy acquired the stake through its wholly owned subsidiary Solrex Pharmaceuticals Company, a partnership firm between Solus Pharmaceuticals and Rexcel Pharmaceuticals.         
	Rambaxy acquired 96,69,977 equity shares of Orchid Chemicals comprising 14.69 per cent of the equity share capital. Singh declined to say if Ranbaxy would increase its stake in the future.         
	Net profit up        
	Ranbaxy has posted a 7.21 per cent growth rate in net profit at Rs 153 crore for the first quarter ended March 31, 2008, compared with Rs 142.7 crore in the corresponding quarter of the previous year. The companys sales rose to Rs 1,623.1 crore from Rs 1,564.4 crore in the year-ago period.                                                                                                                                      
</TEXT> 
</DOC>